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Clinical decisions are most secure when based on findings 
lram several lara randomized cliaical trials. but retwant 
cldar tllsea Databank. clhdcrd char&w1&lks dpallonls 
at Duke Uniwsily Medii Center who mot eligibility 
rquirela~ots for a-b major randomized trial were used in 
The randomized clinical trial is widely accepted as the mwt 
valid method to compare alternative therapies. The strength 
of the randomized trial arises from its rigorous methods (that 
is, prospective data collection, ongoing quality control mea- 
sures. complete follow-up of patients and careful data anal- 
ysis), as well as from its use of random allocation to 
minimize bias due lo lreatmeol selection (I). Because of 
these methodologic strengths, the results of randomized 
trials carry particular weight in therapeutic decision making. 
Despite the acknowledged advantages of randomized 
trals, it has not proved practical to perform such studies to 
answer all question; oicbmca in!erest. Randomized studies 
have not been performed to evaluate widely used therapies 
such as cardiac valve replacement. repair of congenital heart 
disease. coronary an&dasty and arrhythmia wgery. Al- 
though several randomized trials of coronary bypass urgery 
have been performed (2-W. maoagemem questions remain 
about important clinical subgroups of patients (14) wch as 
the elderly (15.16) and those with a low ejectbr. fzlhn (17). 
Nonrandomized obserwtiooal studies (IMI) continue to 
provide important inforontion used in clinical decision mak- 
ing. Analysis of observaliooal data is most likely to be 
adequate when the data are collected prospectively accord- 
ing IO a protocol, with rigorous quality control measures and 
complete follow-up (22.23). Clinical data bases can be de- 
signed to collect data in this fashion. and analysis of such 
data could provide helpful information in resolving lherapeu- 
tic questions. The major limitation of such data is that 
patients chosen lo receive d&rent therapies may differ in 
their inkial prognosis. and possible selection bias may cloud 
the interpretation of study findings (22). Seleciion bias can 
be reduced by using statistical adjustments lo correct imbal- 
ances in known prognostic factors between patient groups 
(23). II has oat yet been shown, however, that such adjust- 
ments can reduce bias to such a low level that reliable 
inferences can he draw. about the effects of therapy. It is Table 1. Variables in Survwal Models 
important to establish the accuracy of such analysts in AF 
comoarison with Ihc rcfcrcnce standard omvided hv ran- sex 
do&cd trials. Conscqucntly. we undc&ok this &dy to Oa,c alcalheleriaalion 
compare the predictions of the prognostic models developed Rinlivhcmia in&x tprogremve win. nnrturn*l Pdl”. preiniwcflonal piin. 
in the Duke Cardiovascular Disease Databank with the pain frewncy 
results of the three m;djor randomized trials of coronary 
Mwardirl damage inrlex ~w”geSl,“e henIl Gl”rc cl.,,. s, g.ll”I. 
artery wrgery in patients with chronic stable angina. 
cardlamegaly. hlrtary of nlyrowdial L”LIEli0”. Q WWII. ,esI ST and T 
WWI changer. premalure “enlri~ulal romp,exer, 
Methods 
Prognostic models. The computerized medical informa- 
tion system used in this study contains standardized clinical 
and laboratory information collected prospectively on all 
patients undergoing cardiac catheterization at Duke Univer- 
sity Medical Center (24). These patients have been followed 
up at 6 months, I !a:ar and annually thereafter, with fol- 
low-up information t :ing 98% complete at all intervals. 
A major goal of the Duke iiniversily Cardiovascular 
Disease Databank ha been to determine pmgnostic factors 
in coronary disease aad to develop mpltivariable statistical 
models that can predict the prognosis of individual patients. 
Prognostic factors h.z:c been detemdqed by analysis of the 
survival patterns in patients with ~15% luminal diameter 
narrowing in a major coronary anery or its large branches 
(25-36). The Cox proportional hazards model (37) has been 
used to develop prognostic estimates and to calculate esti- 
mates applicable to individual patients. These predictions 
have been shown to he reproducible in an indevendenl 
sample (341 and 10 be more ~ccuratc than those oiexperi- 
enced clinicians (38). In developing the prognostic models, 
some variables that describe related aspects of pathaphysiol- 
ogy have been combined into indexes that more closely 
axis 
identify patients at Duke who met ebglhbty criteria for e;lch 
trial and use their baseline information to oredict the results 
of medical and surgical therapy observed in the trial. The 
eligibility criteria of each randomized trial that were applied 
to patients in theCardiovascular Disesse Databank are listed 
in Table 2 (3~5. IO). Predictions of prognosis of patients given 
medical or surgical therapy were then computed for each 
patient meetiy trial ebglblbty criteria. Because the progno- 
sis of both medically and surgically treated patienis with 
coronary disease has been steadily improving over time 
(34,391, prognostic predictions should reflect results at the 
time each trial was conducted. Consequently. patients at 
reflect clinical reasoning and allow for more accurate pros- Table 2. Eligibility Criteria for Three Randomized Trials* 
Qoslic prn+rtion* (V!. “d C,-PP rlQs . . L .,. 
Tl~cfac~ors ued rnplrdicr prognosis irr rite prcwnr srndy 
ore /isred h Table 1. The most Importsot factors in the 
ASC ,yr1 _ <65 a(l5 
prediction of prognosis are measures of IeR ventricular 
Sor Male Male - 
function. the extent and severity ofcoronary atherosclerosis 
Pain !za,,em Stabk Stable stable 
Sylnptam L!uration @lo, 86 a _ 
and the pattern and frequency of symptoms. NYHA alLll,nn Clbll _ _ 
Predictions of randon& &I finding?+. Prediction of the 
prognosis of an individual patient with coronary disease 
requires that all the clinical and laboratory data listed in 
Table I are know. Patienla who are alike in one or two of 
the factors, such as number of diseased vew& and ejection 
fraction, may have a markedly different prognosis if there 
arc differences in woe ofthe remaining prognostic factors in 
Table I (14). Therefore. accurate prediction ofthc prognosis 
of agroup ofpatients requires thatthecharacteristicsof each 
individual patient be taken into account. 
T/w id& fcs! of rhe proenoslic model would be to apply 
it to the individual patients actually enrolled in each random- 
ized trial. Because these data were unavailable. a different 
approach was necessary. The strategy of this study wa to 
Duke who met irial ebgibilily cnler~a but aho underwcni Table 4. Prfdicied and “b\cr”cd 5 Yeer S”rvi”,ll Rater m ihe 
catheterization e:ther before or after the trial’? pat&l entry YL,cr,ln* AdmliiL,lri,tw” Cooperalive S,“dy ,“i, 
period had their prognostac predictno adju\wd to rcflcct Ihc \W!rrl Sarglr.,, 
pmgnosis that would apply ~1 the madpomt of rhai trial’\ 
study period. Predictions of the overall rcruIt\ of each 
cansenre confi,,en<e 
v<dcl v* LirnW \,&I Y,, I/m/l< 
randomized trial were made by averaging the individual 
predictions for all patients from Duke who met the cbgttdity F”$’ ‘” ’ ” ” ‘” ” “” ” ” “” 
criteria for a giucn trial. l.~,Imsl” Mh 0 4ll”li 12, -$I i’,097 
Camparis4m with randomiad trial &dings. For purpn~e, I vc%lc~ ii,I 7s 69 1. 83 u.1 81 75 ,o ~9 
of this study, the primary comparison was between model ? veil x8 ‘) ~3 76 IU 91 WI 9 ?Y m (0 ~6 
predictions and the survival rates observed at 5 yean in Ihe b k\el W (1 88 75 to 95 91.2 %1 8110 W 
medical and surgical groups of the randomirrd trial. Results 
at other time intervals (such as I year or 3 years) were 
‘Wi ‘onhdcnce llmil. v yew WNIYill dnil. CAD = cwmlary *neiy 
tllre,lw “.I = “elu.,“r Adm,n,slmi”n CoopcrallW S,“dS 
comparable: for simplicity, the results arc presented only for 
5 year survival. Comoarisons were atco made between 
model predictions and bbserved randomized mat resubs m I?% 01 patients at Duke with angiographically documrnled 
subgroups defined by the number of diseased WFCB~C. The 5 
year survival rates for each randomized trial used m tbv 
rigmficanr coronary arlery disease. Basclmc chgractcristica 
of patients from Duke who were c!igibtc for tbc Vctemns 
study were those most recently published t4.9.13). Bccausc Adminiatralion &al were similar in most respects to those 
any measurement contains a degree of uncenaimy, 95% patients actually enmlled in that trial (Table 3). The only 
confidence limits for the 5 year survival rate5 observed in major ddfcrsncc between the two study grou;is was that a 
each trial were estimated using the binomial distributmn greater proportion of palienls al Duke than in the Veterans 
(40). The number of patients actually randomtzed was mut- Admmlstretion trial had class IV angma. 
tiplied by the known 5 year survival nw to calcuta~ !he The snr~hol rmrs predicrcd by r/w model esinr the 
nbmber of surviving p&ients, wbmb was lhcn used to clzonzcrrrrsricr qf IIW &uieurs nr .Dtke are compared in 
cnlculate confidence limits. Table 4 with those observed in the Veterans ALministmlion 
trial. The 5 year wwivat rate predIcted for tbc medical 
RCZSUNS 
patiems was 80.9% and the rate actually observed in the trial 
WBI 78% (confidence limits 73 to 82%). The 5 year survival 
Veterans Administration Coqeratire Study. A total of rate predicted for the burgiually treated patients was 85.5%: 
719 patients at Duke met the criteria listed in Table 2 and the rate actually observed in the trial was 83% tsonfidence 
would have been eligible for entry into the Veterans Admin- limits 79 to 87%). Thus. the overall 5 year survival rates 
istntion Cooperative Study. ‘These 719 patients represent predicted by rhc model on the basis of the patienrs from 
Duke who were eligible for the Veterans Administration 
Ptudy were quite close to those ohrerved. falling well within 
the confidence lbmits in both instances. 
Si,bproup& hmnl on wmrbur @ disrrrsvd rornno~ VW 
~4s. The survival rates of patients observed in Ihe Vcterana 
Administration trial. subgrouped according Lo the number of 
diseased vewlc. are also compared in Table d wi!b those 
predicted by the Duke model. Predicted survival rates were 
whin the confidence limtts for the observed survival rates in 
811 subgroup<. except for that of the patients with two vessel 
disease treated surgically. The 98 surgically treated patients 
with two vessel disease in the trial had a 3 vear survival rate 
of 79%. which was welt below the ‘N9%.predicred by the 
model. and also lower than the 81% survival rate of the 135 
patients with tbrec vessel disease randomized to surgery m 
the Irial. The Duke model predicted that the trial patients 
would <how a consistent trend in 5 year survival among 
patients wth one. two and three vessel disease; this wend 
was observed m the medically treated palients. hut not in the 
wgically trcatcd patients in the Veterans Administration 
trial 
European Cooperalive Surgery Study. A total of 512 
patients at Duke met the ebmbdlty criteria listed in Table 2 
and would have been eligible for entrv into the Eurowan 
Cooperative Surgery Stuiy. These 5i2 patients repr&t 
8.6% of patients at Duke with significant coronary artery 
disease documented at coronary angwgraphy. The basei& 
chancteristics of the patients at Duke who were eligible for 
the Eumpean trial are quite similar to those of the patients 
actually enrolled in the study (Table 5). apart from a higher 
prevalence of hypertension and smoking in the patients from 
Duke. 
T/w sun~ivol T(IIPS wedicred bv the model rrriw the 
i!tdividmd characrerisri~s ofthe p&mu al Duke whdwere 
eligible for lhu Enrvpeun lrial are compared in Table 6 with 
those observed in the trial. The predicted 5 year swival rate 
under medical therapy was 86.3%. whereas the observed 
rate in the Eumpcan trial was 84% (confidence limits 79 to 
87%! The 5 year survival rat? predicted for surgically 
treated patients was 91.9%. whereas the observed rate was 
92% (confidence limits 89 to 95%). Thus. in both instances. 
the predicted survival rates were within the confidence 
limits. and quite close to the survival mtes actually ub- 
served. 
The predicted and observed 5 year survival rates in the 
subgroups of patients with two vessel, three vessel and left 
main coronary artery disease are also displayed in Table 6. 
In each instance. the predicted survival rates were within the 
95% confidence limits, and quite close to the values act~lly 
observed. 
Comnarv Arterv Sureerv Stodv ICASS). A total of 250 
patients at Duke met theVc$eria Ii&d in Table 2 and would 
have been eligible for entry into the Coronary Artery Sur- 
gery Study. These 250 patients represent 4.2% of the pa- 
tients at Duke with significsnt coronary aRely disease dof- 
umented by coronary angiography. Baseline characteristics 
of the patients at Duke who were eligible for the Coronary 
Artery Surgery Study differed in se&ml important rape& 
from those of patients actually enrolled in the trial (Table 7). 
In particular. eligible patients from Duke had more were 
angina and more extensive coronary disease, with a higher 
frequency of proximal left anteriordescendingand 50 to 6% 
left main coronary artery lesions than did patients random- 
ized in the trial. 
The snrvivol rates predicred by rhe model using the 
individual characteristics of the porims LII Dttke who were 
eligiblefor the Coronnry Artery Swgery Study are compared 
in Table 8 with those actually observed in the randomized 
trial. The 5 year survival rate predicted for medically treated 
patients WE 87.2% the observed rate was 92% (confidence 
limits 89 to 9.W. The 5 year arvival rate predicted for 
surgically treated patients was Y3.0%, and the observed rate 
was 95% (confidence limits from 92 to 97%). Thus. the 
overall 5 year survival rate predicted by the model was cluse 
to the observed surgical results. but the survival rate of the 
patients randomized to medical therapy was much better 
than predicted. This discrepancy. which could be due either Table v. Clmprtlson Of Panem Randomized in CASS Widl 
to prediction by rbe model of an mappropriatrly low s~r~wnl CASS R~ndomiruble and Eli@,lc Ovkc Wdcntr I%, 
rate for medical patients or to an anomalously high burvi~al 
rate of patients randomized to medical therapy in the Coro- CASS 
CASS R*“d”miwblr DuxI 
nary Artcry Surgery Study. will be examined in detad next. 
Ra”dOi2lWd Medical Surwl Fl,g,hlr 
~ 
Role ofmslriversel diwase md urmricolur fimnion. The c4D 
predicted and observed 5 year s~rvtval rates for the panent i II:::! 
subgroups with one. two and three vcs~el disease with ather ; yc,i., 
normal or depressed left ventricular function are also dis- ~~~~~~~~ L.,D 
played in Table 8. The model predictions are within :he 95% ~rri hl;lln 
confidence limits of observed randomized trial results in all 
but one subgroup. namely. patients with three vewl disease 
and normal left ventricular function randomized to medical 
therapy, who had B 5 year survival rate much higher than 
that predicted by the model. It is notewonhy ihat the Duke 
model predicted that the 5 year survival rate should progrcs- 
sively decrease among the medically treated patients with 
one, two and three vessel disease and normal ejection 
fraction. but the survival rates observed in the randomized 
trial in these three subnmuos were essentiallv Ihe same. 
Differences in pa&t chbrocler&ics. Cl& examinatmn 
of the baseline characteristics listed in Table 7 shows that 
random&tion.in the coronary Artery Surgery Study were 
not randomized. This hypothesis is supported by ccmpari- 
patients at Duke who met the ekglhdnty requirements for the 
Coronary Artery Surgery Study were. in a variety of ways. 
sun of the patients actually randomized with the patients 
sicker than patients actwdly randomized in the uial. The 
patients at Duke had more severe chest pain, a greater 
who were eligible for randomization but who were not 
incidence of three vessel disease and almost twice the 
randomized (41). Patients eligible for randomization with a 
frequency ofdisease in the proninral leli anterior descending 
coronary anatomy at higher risk (such as those with three 
coronarv arterv. It is possible that such oatients elieibk for 
vessel disease. 50 ID 6% left man stenos,s or proximal left 
antenor descending coronary artery stenosis) were fre- 
quently wrhdrawn from randomiration and sent to surgery 
(Table 9). The patients ar Duke who were eligible for the 
Coronary Artery Surgery Study more closely resembled the 
patients ehgible for randomization who were withdrawn and 
sent to ,twerv (Table 91. 
Compa&o~s among trials. The consistency of findings in 
several different studier supports stronger conclusions for 
clmical management than do Ihe findings of a cmgle study. 
The selection criteria for the three major randomized trials 
were different. but similar clinical subgroups have been 
studied m more than one trial. 
displayed in Fig& I. along with the predictions of the 
prognostic mudel based on the patients from Duke who were 
eligible for each trial. It is apparent that in both trials the 
Parims wit/t sign$cacnn~ /efi win coronnry ormy diseme 
were enrolled m both the Veterans Administration study and 
the European studv. The rzwits of there two tnats arc 
Figure 1. Comparison of predicted and observed IUN~YB~ m!es far 
paenn wilh left main coronary artery disease in the Veterans 
Administradon ,“A, Cwoemtive Stud” and Ibe Eumrr~an Cooeer. 
alive Surgery Study U&S). The topoieacb bsrind&es the u&r 
95% confidcncc limit, Ihe batem oftb+ bar indicates Ihc lower 95% 
confidence lbm~t and the large srnvpl line indicates the observed 
survival raw. The et& b each pawt mdicater the wvival rate 
predicted by the Duke prognostic model. Y = medical therapy: S = 
sur~,caI theraw. 
EC55 c*ss 
Figure 1. Comparison of predicted and observed survival rates for 
patients with three vessel ccronary artery disease and normal eft 
ventricular ejection fracrion m the EUrOpean Cooperative Surgery 
Study WSS, and the Coronary Artery Surwy Study ICAW. 
Format as in Figure I. M = medical therapy: S = surgical Iherapy. 
50 a0 
,“,I& 
90 100 
Figure 4. Plot of survival rater predicted by the Ouke model 
(harizontsd sxls) and survival r&es observed in subgroupr of the 
randomized trials (vertical axis). Data arc replotted from Tables 4,6 
and 8. 
palients with left main coronary artery disease treated snr- 
gically had a substantially higher survival rate than did those 
treated medicallv. Furthermore. the oredictions of the Duke 
pmgnostic n&l are consistent wiih the findings of both 
wialr. Thus, the evidence drawn from both randomized trials 
and analysis of observational data iu convistenl and strongly 
suppons rhe use of surgery in patients with left main disease. 
-. . 
trials. (Long-term resulrs ir. 1hi: subgroup have not been 
reported by the Veterans Administrarion study.) The 5 year 
survival rates observed in these two studies, as well as the 
prcdiclions by the Duke prognostic model, are displayed in 
Figure 2. It is evident hat the two randomized trials reported 
substantially diRerent results in this group of patients. The 
agreement between Duke model predictions and the findings 
of each trial is closer than the agreement between the two 
randomized studies;. 
Figure 3. Camparisma of predicted and observed survival rates for 
medical OI) and surgical 6) patients in Ihe Veterans Administration 
WA) Cooperative Study, the Eurupcsn Coopcralive Surgery Study 
(EC%) and the Coronary Awry Sursery Study KASS). Forma, as 
in Rgwe I. 
Overall agwntent nf predictions with randomized trial 
hdinps. The overall level of agreement between predicted 
and observed survival rates for each randomized trial is 
dis!Wed in Fieure 3. The predictions of the overall trial 
r&It; were within the 95& confidence limits of the ob- 
served survival rates in all but the Coronary Artery Surgery 
Study patients randomized lo medical therapy. The agree. 
ment between predicted and observed survival rate$ for all 
subgroups of the three major randomized trials is plotted in 
F&e 4. The Spearman correlation coeilicient between 
aredicted and observed survivals is 0.73 (a < O.ooOl1. The 
best fit regression line is (observed &ival) = I:08 x 
(predicted survival) - 0.08, which is not significantly dif. 
ferent from Ihe line of identity. 
Discussion 
The major finding of this study is that appropriate stafis- 
tical analysis of carefully collected prospective observa- 
tional data can accurately predict the resuhs observed in the 
three major randomized trials of coronary bypass surgery. 
Taken as n whole. the relation between predi&ns and the 
observed results could not be distinauisbed from a line of 
identity (Fig. 4). Moreover, in 24 (92%) of 26 subgroups, the 
predicted results were quife close 10 those actually ob- 
served. These findings support the contendon lhaf careful 
mullivariable analysis ofobservational data can complement 
rhe findin@ of randomized trials in assessing the results of 
different herapies. 
Analysis of observational data to identify prognaslic fac- 
tors. Such analvsis is widelv accented. hut use of these data 
to evaluate the efficacy oi the& r&nains controversial. 
Virtually all observers agree that a dramatically effective 
thenpy can be quickly accepted into practice without need 
for a randomized trial. Antibiotic treatmrnt of endocarditis 
and electrical defibd!lation are two thxapies that were 
quickly shown to core disorders that had alway? been fatal. 
Simple observation of the dramadc effects of thece thcrapin 
has convinced physicians of !lwr cdicacy. such that a 
randomized study would now he considered onethud. In 
evelooting the recolrs of mo<t therapics, however. either the 
outcome of untreated discasc is more variable or the et&t of 
therapy is less dramatic. or both. Favorable observations of 
the results of a new therapy may not be convincing because 
patients with a favorable prognosis may huve been chosen to 
receive the new therapy. A proper companwn of therapies 
most encore that the treated and control groups are compa- 
rable and that the two groups woold bare bad identical 
outcomes if given the same treatment. The comparability of 
patients can be ensured by randomization. which also per- 
mits calculation of the probability that observed rc~ults may 
he due to chance variation. The scientific advantages of 
randomization are recognized. but a number of practical 
obstacles exist to conducting randomized trials, and most 
clinical studies continue to he nonrandomized. 
When patients are not randomized. the comparobi!ity of 
tree’? and control groups can be improved by using statis- 
tica, u&hods to correct for imbaleonces ia known Frognostic 
factors between treated and control groups. Moldvnrieb!e 
statistical methods act to “subtract “of” the effects of 
confounding prognostic factors and isolate the effect of 
Ireatment. In addition to evaluating therapy. this approach 
provides important insights into the clinical course ofillnws. 
In principle. perfect knowledge of prognostic factors in a 
given disease would allow the statistical analysis to a~ess 
accurately the effects of therapy. In pmctice, knowledge of 
prognostic factors is imp&e;;, ami stati5tical analysis of 
observational data can never completely eliminate the effect 
ofconfounding prognostic factors. An observational analysis 
is, therefore, most reliable when either pmgoostic factors in 
adisease are well understood or the treatment &et is large. 
or both. 
Data bases ia cardido#y. Observational data bases that 
collect information prospectively according to o protocol 
share many of the methodologic strengths of clinical trials. 
Well known da!? b&es in cardiolow include the Coronarv 
Artery Surgery Study Registry (15~21). the Percutaneoo~ 
Tronslominal Coronary Angioplasty Registry (42). the Sear- 
de Heart Watch (43) and the Duke Cardiovaswtar Disease 
Databank (24-36). Because these approaches do nor inter- 
fere with clinical practice. they are relatively sim&r :z 
implement and easier for physicians aoo Padents 10 accept 
than randomized studies. Analysis of such observational 
data could answer many pressing clinical questions. Xefore 
such analyses can he accepted. it most he shown that the 
that corefolly developed prognostic models can he used to 
as~cs~ Ihc effect of revaxularirat~on on prognosis. 
Clinical imptieations. There are several important impli- 
cations of these findings. First, a validated model of prog- 
nosis m coronary artery diccase can he used to assess the 
effect of bypas\ surgery in particular groups of patients that 
were either underrepresented or excluded from randomized 
itudia. Many patients with coronary artery disease were 
nm enrolled in any randomized trial. The etficacy of bypass 
aorgery in patients >65 years of age is not only an imponant 
clmical quertion, but is also h major iswe for health policy. 
Patreots with markedly reduced left ventricular function are 
frequently encountered in practice, bm have not been in- 
cluded m randomized studies of coronary bypass sorgery. 
Other groups of patients may have been included in raodom- 
ired crud~es in such small numbers that definitive cooclo- 
smns are ddcult. Women. for example. were enrolled only 
in the Coronary Artery Surgery Study. and data concerning 
their outcome have not been published separately. To the 
extent that thew and other imponant clinical subgroups are 
well represented in the observationat data hasc. our findings 
soggext that Ihe Duke prognostic models could be applied 10 
asxss the results of bypass surgery with some contidescc in 
the validny of the analysis. 
Am~!hrr tdurbC applicalion of the multivuriabk prop- 
wsrir nmd~ls is ru examine whether n therapy is porficrdwly 
e,j%ariorrs b diffmnr .mbgm,,s o,‘po,ienrs. In an atempt 
to Provide such information, the results afa randomized trial 
are commonly presented according to different levels of 
clinically meaningful factors, such as one. two and three 
vessel coronary artery disease. The size ofeach subgroup is 
always much smallei than the sample size for the whole trial. 
increasing the amount of random variation observed in 
outcome. Random variations not only make it more difficult 
to establish statistical significance in multiple subgroups, but 
coo lead to frankly inconsistent results. In the Veterans 
Administration study (4). for example, patients with two 
vessel oiseose treated surgically had a worse outcome (79% 
5 year survival rate) than did patients with three vessel 
disease treated surgically (81% 5 year survival rate). This 
result is almost certainly an anomaly doe to random varia- 
tion in a small subgroup because it is inconsistent with a 
large body of data showing that patients wth two vessel 
disease have a better prognosis than do those with three 
vessct disease. A prognostic model smooths out such sotis- 
tical fluctuations and relates the results in different suh- 
groups in a consistent fashion. The multivariable analysis is 
particularly able to identify the portion of the disease spec- 
from that receives disproportionate benefit from therapy 
(231. 
analysis if observational hata agrees with the reference One oJ rhr more usefid roles for prognos:r: models is IO 
standard-the randomized trial-in similar patients. The reconcile ,,w dispamre wsolts uf sepnmre mndmnized trio/s. 
agreement between results of randomized trials and the It is now widely accepted that even several randomized 
analysis of observational data in the present study suggests studies may not he sufficient to settle a therapeutic question. 
Only when ~esuks of a dozen or more trials of beta- available, patients at Duke who met entry criteria were used 
adrenergic blockers for secondary prevention after myocar- as proxies for the patients actually enrolled in the 1Ms. 
dial infarction (441 or of intravenous streptokinase for acute Patients from Duke may have differed from those enrolled in 
myocardial infarction (45) were analyzed together did a the randomized trials (and indeed were quite different in the 
consistent &ore emerge. There me, however, few trials of case of Coronarv Arterv Suraerv Studv medical oatients) 
corooary bypass surgery in padents with stable angina. and 
their findings are not completely consistel. The Veterans 
Administration study and the European trial both showed a 
pmnounced treatment benefit from surgical treatment of left 
main coronary artery disease, as did analyses of observa- 
tional data. The consistency ofthis finding imm one study to 
another (and in studies of ditferent design) has led to a 
cor~senso~ that surgery is indicated for left main coronary 
artery disease. In comrast. in patients with three vessel 
disease and normal left vemricutar function. the European 
study found survival to be prolonged (9). and the Coronary 
Artery Surgery Study found no diLrence in survival (10.13). 
Which trial is “right”? 
Artery Surgery Study patients randomized to medical the;- 
spy, however, had a much better prognosis than predicted 
by the model. Model predictions were based an all patients 
from Duke who met trial eligibility criteria, but the Duke 
The Duke prognoslic model offers ~1 mnkod 10 place 
See fi,tdbrnl in u conrisrenr liwnework. The observed 
w&l rat& of pmicnts in theEuropean study were con- 
sistent with the predictions of the model. The Coronary 
and. therefore. ii is not certain ihetherdiscrepaocies were 
due to deficiencies in the prognostic models. Second, the 
Conebtsimu. Predict&of pr&ostic models based on 
models used in this study estimate the effect of surgical 
therapy illdirectly by the difference in medical and surgical 
multivariable Cox analyses ofobservational data in the Duke 
prognoses. Because the effect of surgery on prognosis caw 
not be observed directly in an individual patient, this limita- 
Cardiovascular Disease Databank are in close agreement 
tion is common to all empirical mmlyses. Third, the confi- 
dence limits in the obseived randomized trial results are 
with the remdts observed in the three major randomized 
large enough that small discrepancies between predictions of 
the Duke models and randomized trial results could have 
remained undetected. Very small discrepancies, however, 
would be of little practical importance. Finally. this study 
concerns the predictions of particular prognostic models, 
which were developed in a very large group of patients. This 
study does not, however, provide evidence that all multiva- 
riable prognostic models are accurate. Each prognostic 
model must be validated seoaratelv. 
padents more cutely resembled the Coronary Artery Sur- 
gery Study patients who were withdrawn from raodomiza- 
lion sod sent to surgery (Table 91. The oatients randomized 
in the Coronary Artery Surgery St& appear to be at 
unexpectedly low risk. In fact. the patients with a normal 
ejection fraction randomized to medical therapy had survival 
probabilities quite similar to those of patients without sienif- 
icam coronary disease in the Coroner; Artery Surgery Study 
Registry (46). The patients in the Coronary Artery Surgery 
Study randomized trial had such a low risk that the usual 
trend in prognosis from one to three vessel disease was not 
evident. 
A rcconciliarion of rhe results from rhe Coronq Arrery 
Siwerv Study and rhc Ewoocan trial is suavsted bv the 
opp!icc:ion o.f tke Duke pro&stic model. ~&pean &dy 
patients were at relatively high risk. whereas Coronary 
Artery Surgery Study patients were at relatively low risk. If 
both trials are accepted as correct in their patient poputa- 
lions, the results suggest that high risk patients with three 
vessel disease receive a survival benefit from surgery, 
whereas low risk patients, such as those randomized in the 
Coronary Artery Surgery Study. do not appear to benefit. 
Thus. patient selection for surgery should depend on identi- 
fying the high risk patient. 
Limitations. There are several limitations to this studs. 
First, we were unable to predict the results of randomized 
trials urine. the clinical findines of the individual oaticnts 
actually &rolled in each trial.&aose these data were not 
trials of coronary bypass surgery. These pr&nostic models 
may be used to make an individual prediction of prognosis, 
provide insights into the clinical determinants of prognosis in 
coronary disease. reconcile disparate randomized trial re- 
sults and atwwr therapeutic questions for which there are 
no relevant randomized trial dale. 

